Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still BuysThe Motley Fool • 07/03/23
For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayMarket Watch • 06/30/23
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)Business Wire • 06/27/23